MSIA Workflow for Therapeutic Antibodies: Qualitative, Quantitative, and Functional Verification Data from HR/AM Detection of Intact, Reduced, and Peptide-level Forms of Adalimumab

This application note illustrates an innovative and versatile MSIA Workflow approach to therapeutic antibody analytics, using adalimumab in human donor plasma as a model biological system and subsequent analysis by three distinct mass spectrometry detection formats: Intact, Reduced, and Bottom up. The biopharmaceutical industry has adopted biologics as a major component of their drug portfolios and developing pipelines. The rapid adoption of this class of biologics is due to their high affinity for their targets, selective biological actions, predictability of common side effects, and standardization of manufacturing processes.